BioMarin, Summit Sign Agreement for Muscular Dystrophy Program

BioMarin Pharmaceutical and Summit Corporation plc announced that they have entered into an exclusive worldwide licensing agreement for Summit’s novel preclinical candidate SMT C1100 and all follow-on molecules, which are being developed to treat the fatal genetic disorder Duchenne muscular dystrophy (DMD).
The Earth Times